BioPharma Clinical Trials
Excyte Doses First Patient in Global Trial of YK012, the First T Cell Engager for Primary Membranous Nephropathy
Excyte, a global clinical-stage biotechnology company, announced first patient has been dosed for YK012, the world’s first patient T cell engager tha...
June 03, 2025 | News
Protagonist Therapeutics and Takeda Report Positive Phase 3 Results for Rusfertide in PV, Meeting All Primary and Secondary Endpoints
Rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phleboto...
June 03, 2025 | News
Huonslab Completes Patient Enrollment for Pivotal Phase 1 Trial of HLB3-002 in South Korea
Phase 1 Pivotal Study in Korea for HLB3-002 Plans to apply for marketing approval with the MFDS by the 2H 2025 -Huonslab Co., Ltd. (&ldq...
May 27, 2025 | News
Celltrion’s YUFLYMA® Wins Expanded Interchangeability Status for All Humira® Dosage Forms in the U.S.
YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar[1] Cellt...
May 26, 2025 | News
DualityBio and Avenzo Receive FDA IND Clearance for Novel EGFR/HER3 Bispecific ADC
Duality Biotherapeutics partner Avenzo Therapeutics, Inc. a clinical-stage biotechnology company developing next-generation oncology therapies, announced c...
May 23, 2025 | News
Minghui Doses First Patient in Phase II Trial of PD-1xVEGF Bispecific and TROP-2 ADC Combo for Advanced NSCLC
Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative therapies in immunology and oncology, announced that ...
May 21, 2025 | News
AstraZeneca’s AIRSUPRA Cuts Severe Asthma Exacerbations by 47%, Redefines Mild Asthma Treatment Standard
AIRSUPRA demonstrated a 47% reduction in the risk of severe exacerbations in mild asthma compared with albuterol alone Full results published in th...
May 20, 2025 | News
Xuanzhu Biopharmaceutical’s Bireociclib (Xuanyuening®) Approved in China, Setting New Benchmark in HR+/HER2- Breast Cancer Treatment
National Medical Products Administration attracted widespread attention in the oncology community and the pharmaceutical market. Bireociclib tablets (trade...
May 19, 2025 | News
Nordic Bioscience Launches nordicEndotrophin™ to Advance Risk Stratification and Monitoring in Fibrosis and Cancer
Nordic Bioscience introduces nordicEndotrophin™, a fully automated high-precision assay that selectively quantifies the intact 77-amino-acid Endotrop...
May 19, 2025 | News
InnoCare Pharma Doses First Patient in Phase II/III Trial of Soficitinib for Vitiligo in China
InnoCare Pharma a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has...
May 19, 2025 | News
Shanghai Ark Biopharmaceutical Announces Positive Phase II Results for AK3280 in Idiopathic Pulmonary Fibrosis
Shanghai Ark Biopharmaceutical Co., Ltd. announced positive top-line Phase II study results for its novel anti-fibrotic drug AK3280 in treatment of id...
May 16, 2025 | News
InnoCare’s Mesutoclax Becomes First BCL2 Inhibitor to Receive Breakthrough Therapy Designation in China
-InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced&nbs...
May 13, 2025 | News
EnGeneIC Doses First Patient in Phase I/IIa Trial for EGFR-Positive Solid Tumours at Mater Hospital, Sydney
First Patient dosed in Phase I/IIa Basket Trial for Solid Tumours at Mater Hospital, North Sydney Recruitment to open this month at Frankston Hospital, ...
May 13, 2025 | News
Minghui Pharma Licenses B7-H3 ADC MHB088C to Qilu for Greater China in RMB 1.345 Billion Deal
Minghui Pharmaceutical , a late-stage clinical biopharmaceutical company, announced an exclusive licensing and collaboration agreement with Qilu Phar...
May 12, 2025 | News
Most Read
- Bridging the Vision Gap: Roche’s Ahmed Elhusseiny on Eye Health Priorities in Asia Pacific
- How Merck’s India-Based Navi Mumbai Centre is Reimagining Formulation Science for the Global Generics Market
- Advancing Cell & Gene Therapy in APJ: How Thermo Fisher Enables Breakthrough Innovation
- AstraZeneca’s Vision for Chronic Kidney Disease: Sylvia Varela on Transforming CKD Care in Asia
- ACG Leads the Charge in Vegan Capsules: Innovation, Certification, and the Future of Sustainable Pharma
- ORA’s Hybrid Model Reshapes Obesity Care: Dr. Ben Ng on Bridging Telehealth and In-Person Treatment
- Heather Hargett on How Merck’s HUB Organoids Acquisition is Reshaping 3D Cell Culture and Drug Development
- Health2Sync's Vision for Diabetes Care: Transforming Outcomes Through Technology and Partnerships
Bio Jobs
- Ravindra Rao Joins GOBI Technologies as Director of Life Sciences – APAC
- Amgen Announces $900 Million Expansion of Ohio Biomanufacturing Facility, Boosting Investment to Over $1.4 Billion
- Thermo Fisher Scientific Appoints Former CVS Health CEO Karen S. Lynch to Board of Directors
- Merck KGaA Reshapes Leadership for the Future with Key Executive Moves
- Aarian Health Appoints Thomas Keller as Business Director to Drive Innovation and Growth
- Top Management Shakeups of 2024: Redefining Pharma, Biopharma, and Biotech Leadership
News
Editor Picks
